Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study

about

Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: recommended schedule for expected activity and safety and phase II study

Item

http://www.wikidata.org/entity/Q58796906

description

im August 2018 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 07 August 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

Real life triplet FIr/FOx chem ...... and safety and phase II study

@en

Real life triplet FIr/FOx chem ...... and safety and phase II study

@nl

type

Item

label

Real life triplet FIr/FOx chem ...... and safety and phase II study

@en

Real life triplet FIr/FOx chem ...... and safety and phase II study

@nl

prefLabel

Real life triplet FIr/FOx chem ...... and safety and phase II study

@en

Real life triplet FIr/FOx chem ...... and safety and phase II study

@nl

P1476

Real life triplet FIr/FOx chem ...... and safety and phase II study

@en

P2093

Aldo Victor Giordano

http://www.w3.org/2001/XMLSchema#string

Alessandra Di Sibio

http://www.w3.org/2001/XMLSchema#string

Antonio Russo

http://www.w3.org/2001/XMLSchema#string

Enrico Ricevuto

http://www.w3.org/2001/XMLSchema#string

Eugenio Ciacco

http://www.w3.org/2001/XMLSchema#string

Gemma Bruera

http://www.w3.org/2001/XMLSchema#string

Oncology Network ASL1 Abruzzo, Italy

http://www.w3.org/2001/XMLSchema#string

Rosa Manetta

http://www.w3.org/2001/XMLSchema#string

Sergio Carducci

http://www.w3.org/2001/XMLSchema#string

Silvia Massacese

http://www.w3.org/2001/XMLSchema#string

P2860

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Pancreatic cancer

Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine

Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

"Poker" association of weekly alternating 5-fluorouracil, irinotecan, bevacizumab and oxaliplatin (FIr-B/FOx) in first line treatment of metastatic colorectal cancer: a phase II study.

Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial.

Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial.

P304

31861-31876

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.25870

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Antonio Galvano

P577

2018-08-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30159128

http://www.w3.org/2001/XMLSchema#string

P921

adenocarcinoma

chemotherapy

P932

6112758

http://www.w3.org/2001/XMLSchema#string